Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Robert Lipshutz, Christian Cabou, Stephen Worland

Premium

The Institute for Systems Biology has appointed Robert Lipshutz to be chief business officer and senior vice president for strategic partnerships.

Lipshutz spent nearly two decades at Affymetrix in various roles, focusing on business development, licensing, diagnostics, and emerging markets, and most recently was Affy's senior vice president for corporate development.


Illumina said last this week that Christian Cabou, who is senior vice president, general counsel and secretary, has notified the company that he plans to retire sometime early next year.

Cabou has worldwide responsibility for all of the company's legal and intellectual property matters and is also Illumina's code of ethics compliance officer. Prior to joining Illumina in 2006, Cabou was general counsel for GE Global Research.


GenMark Diagnostics said last week that Stephen Worland has been appointed to its board of directors.

Worland is currently president and CEO of Effector Therapeutics. He was president and CEO and a director of Anadys Pharmaceuticals from 2007 until the company was acquired by Roche in 2011.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.